Fabian Zanella
About Fabian Zanella
Fabian Zanella is the Director of Analytic Testing at Sana Biotechnology, Inc., where he has worked since 2020. He has extensive experience in cell biology and regenerative medicine, having previously held leadership roles at StemoniX and conducted research at UCSD School of Medicine.
Current Role at Sana Biotechnology
Fabian Zanella serves as the Director of Analytic Testing at Sana Biotechnology, Inc. since 2020. In this role, he is responsible for overseeing analytic testing processes that support the development of innovative therapies. His work focuses on leveraging human induced pluripotent stem cells (hiPSCs) to advance applications in cell therapy and regenerative medicine. Zanella's expertise in creating physiologically relevant cell-based platforms enhances the company's capabilities in drug discovery and safety assessments.
Previous Experience at StemoniX
Before joining Sana Biotechnology, Fabian Zanella held multiple roles at StemoniX from 2015 to 2020. He began as the Director of Research and Development, where he led teams in developing products utilizing hiPSC-derived cardiomyocytes, neuronal, and pancreatic cultures. He also served briefly as the Senior Director of Research and Development in early 2020. His tenure at StemoniX contributed to advancements in high throughput screenings and innovative platform development.
Academic Background and Research
Fabian Zanella earned his PhD in Molecular Biology, Biochemistry, and Biomedicine from Universidad Autónoma de Madrid, where he studied from 2005 to 2009. Prior to this, he completed a Bachelor of Science in Biology at Universidade do Porto from 1999 to 2004. His post-doctoral research at UCSD School of Medicine from 2010 to 2015 further solidified his expertise in cell biology and regenerative medicine, focusing on applications of hiPSCs.
Expertise in Cell-Based Platforms
Zanella specializes in developing physiologically relevant cell-based platforms that demonstrate differential pharmacological responses. His work addresses significant gaps in current cell-based models for drug discovery and safety. He has a successful track record in leading teams to create innovative solutions using advanced cell-based platforms, which are essential for the advancement of therapeutic applications.